Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
Sponsor: Michael Ohliger, MD PhD
Summary
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the progression of fatty liver disease in vivo. The purpose of this pilot study is to optimize sequence parameters for hyperpolarized 13C acquisition in the human liver and determine which metabolic changes can be seen in humans with simple, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) when compared to healthy volunteers.
Official title: Pilot Study of Magnetic Resonance Imaging With Hyperpolarized Pyruvate (13C) In Patients With Fatty Liver Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
44
Start Date
2020-07-22
Completion Date
2025-08-28
Last Updated
2026-08-03
Healthy Volunteers
Yes
Conditions
Interventions
Hyperpolarized (HP) 13C
A dosage of 0.43 mL/kg body weight at the maximum dosage will be injected intravenously at a rate of 5 mL/second.
Hyperpolarized 13C-Urea
Given intravenously (IV)
Magnetic Resonance Imaging
Imaging procedure
Saline Flush
A 20 milliliter (mL) saline flush at 5 mL/second will be given after each dose of HP 13C
Locations (1)
University of California, San Francisco
San Francisco, California, United States